此外，公司通过北京贝黎诗及上海美丽田园医疗健康，(i)于2025年11月28日根据11月28日认购自浦发银 行认购金额为人民币1000万元；(ii)于2025年11月21日根据11月21日认购自浦发银行认购金额为人民币 7000万元；(iii)于2025年10月9日根据10月9日认购自浦发银行认购金额为人民币8000万元的保本理财产 品，上述所有产品于本公告日期均仍尚未到期。 格隆汇12月30日丨美丽田园医疗健康(02373.HK)公告，于2025年12月30日，为有效利用闲置资金，北京 贝黎诗根据12月30日认购自浦发银行认购总金额为人民币8000万元的保本理财产品。 ...

Core Viewpoint - The company acknowledges the challenges posed by the central economic meeting's decisions regarding the healthcare sector in 2026, but emphasizes the potential for new development opportunities through strategic adjustments and operational improvements [1] Group 1: Industry Response - The central economic work meeting has outlined a commitment to high-quality development in the healthcare sector, focusing on "three medical collaborations," optimization of drug procurement, and reforms in medical insurance payment methods [1] - These policy changes will raise expectations for all medical institutions, indicating a shift towards higher operational standards and efficiency [1] Group 2: Company Strategy - The company plans to adhere to its strategic objectives by maintaining stable operations, enhancing cost control, and improving efficiency [1] - Emphasis will be placed on improving medical quality and patient service experience, alongside strengthening discipline construction and optimizing the patient service system [1] - The company aims to build competitive advantages through differentiated strategies, enhancing service value, and adapting to industry changes for orderly expansion and continuous operational efficiency improvement [1]

Core Viewpoint - The company is conducting a private placement of shares to raise funds for long-term strategic development, addressing investor concerns regarding potential misuse of funds and the impact on shareholder equity [1] Group 1: Fundraising Details - The total amount to be raised through the private placement is not exceeding 1,007.54 million yuan [1] - The funds will primarily be allocated to three projects: Smart Elderly Care Project, Phase II of the Proton Therapy Center, and working capital supplementation [1] Group 2: Project Allocations - The Smart Elderly Care Project has a total investment of approximately 751 million yuan, with about 638 million yuan planned to be raised, aimed at capitalizing on the "silver economy" [1] - The Phase II Proton Therapy Center project has a total investment of 99.93 million yuan, with the entire amount to be funded through the private placement, targeting the gap in the proton therapy market in Northwest China [1] - The working capital supplementation is set at 270 million yuan, intended to optimize the company's capital structure and enhance ongoing operational capabilities [1] Group 3: Strategic Intent - The private placement aligns with national policies and is a proactive choice based on the company's development strategy, aiming to seize industry growth opportunities and improve asset utilization [1] - The company emphasizes its commitment to maintaining proper operations and protecting the legal rights of all shareholders, particularly minority shareholders [1]

Core Viewpoint - The company acknowledges ongoing financial pressures despite previous fundraising efforts, emphasizing the need for strategic adjustments to improve performance and capitalize on market opportunities [1] Group 1: Financial Performance - The company completed a 1 billion yuan private placement in January 2021 to support liquidity and repay bank loans [1] - The company has experienced a compound annual growth rate (CAGR) of 33.28% in revenue over the past three years, indicating growth in business scale [1] - Continuous losses have led to a cycle of borrowing and increased costs, necessitating urgent solutions to break this pattern [1] Group 2: Strategic Initiatives - The recent private placement aims to align with national policies and seize opportunities in the "silver economy" [1] - The company is focused on optimizing its capital structure and revitalizing existing assets to lay a solid foundation for future growth [1] - There is an emphasis on enhancing capabilities in the cancer treatment sector to meet future funding needs and improve operational sustainability [1]

Core Insights - The article highlights the successful implementation of the "Hangzhou Municipal Health Promotion Regulations," which aims to enhance public health and well-being in the city, achieving a health literacy level of 46.52% and a life expectancy of 84.18 years by 2024 [1][6] Legislative Framework - The "Hangzhou Municipal Health Promotion Regulations," effective from January 1, 2026, establishes a comprehensive health security network with 54 articles, transforming the concept of "health priority" into a binding obligation [1][4] - The introduction of a dedicated chapter on "Health Impact Assessment" makes Hangzhou the first city in China to formalize this system through local legislation [1][2] Public Health Initiatives - The regulations emphasize inclusivity, ensuring that migrant workers are included in medical insurance, which has been positively received by non-local workers in the city [4] - The establishment of smart health stations in rural areas allows for online access to health records, ensuring that even remote communities benefit from precise medical services [4] Community Health Services - The "Health Village Chief" initiative in rural areas provides free medical consultations and health education, demonstrating the practical application of the health regulations [7] - The development of 20 health "premium routes" integrates health education into recreational activities, promoting a healthier lifestyle among citizens [9] Technological Integration - The use of AI in health services enhances efficiency, with all grassroots medical institutions connected to diagnostic support systems, conducting over 2.22 billion quality control checks on medical records [13][16] - Digital platforms like "Family Doctor Appointment" have engaged over 1.17 million residents, facilitating communication and health reminders, showcasing the integration of technology in health management [16] Overall Impact - The comprehensive health governance model in Hangzhou illustrates the importance of integrating health into all policies, leading to improved public health outcomes and community well-being [11][17]

（文章来源：证券日报） 证券日报网讯 12月30日，光正眼科发布公告称，光正眼科第六届董事会第七次会议审议通过《关于 2026年度日常关联交易预计的议案》等。 ...

Core Viewpoint - The company announced that its subsidiary, Guangzhou Taihe Oncology Hospital Proton Therapy Center, has officially operated for one year since December 16, 2024, emphasizing its commitment to enhancing clinical capabilities and international collaboration in proton therapy [1] Group 1: Operational Performance - The Guangzhou Proton Therapy Center has fully utilized its four treatment rooms, providing proton therapy services to a total of 550 patients, with over 80 new patients added each month [1] - The center's patient demographic spans across 31 provincial administrative regions in China and over 20 countries and regions, with patients ranging in age from 1 to 91 years old [1] - The center completed China's first proton therapy for choroidal malignant melanoma in July 2025, marking a significant milestone in its operational achievements [1] Group 2: Strategic Development - The company is focused on strengthening its core competitiveness in high-end medical services through continuous optimization of service processes and improvement of treatment efficiency [1] - The steady advancement of the proton therapy business has further enhanced the company's layout in the field of precision cancer treatment [1] - Future plans include ongoing enhancements in clinical capabilities and collaboration with advanced international medical institutions to keep pace with global developments in proton therapy technology [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院質子治療中心（以下簡稱「廣州 醫院質子中心」）自2024年12月16日起至今，已正式運營一周年。公司高度重視 質子治療中心的臨床能力建設，堅持加強與國際先進醫療機構合作科研，與國際 質子治療技術同步發展，通過引進高端醫療人才、加強技術研發與學術交流等方 式，持續提升診療水平。截至目前，廣州醫院質子中心的臨床服務能力已得到充 分驗證，各項運營指標表現良好。 廣州醫院質子中心四間質子治療室已經全部啟用，累計為550位患者提供質子治 療服務，單月新增患者超過80人，服務能力持續提升。服務患者範圍覆蓋國內31 個省級行政區以及20多個國家和地區，接受質子治療的患者年齡從1歲至91歲。 2025年7月，廣州醫 ...

12月30日，药明康德大宗交易成交7.17万股，成交额659.64万元，占当日总成交额的0.23%，成交价92元，较市场收盘价91.9元溢价0.11%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2025-12-30 | 药明康德 | 603259 | 92 7.17 | 659.64 | 广发评荣降盆冥蟹 | 中国银河证券股准 有限公司使 | ...

Core Viewpoint - The company is currently in the construction phase of its internet hospital project and has not yet officially launched operations [2] Group 1: Company Developments - The company established "Harbin People's Tongtai Cloud Medical Internet Hospital Co., Ltd." in March 2025 and obtained relevant online medical service qualifications [2] - As of now, the internet hospital project is still under development and has not commenced formal operations [2]